A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of AG-120 in Previously-treated Subjects With Nonresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation
Phase of Trial: Phase III
Latest Information Update: 28 Mar 2018
At a glance
- Drugs Ivosidenib (Primary)
- Indications Cholangiocarcinoma
- Focus Registrational; Therapeutic Use
- Acronyms ClarIDHy
- Sponsors Agios Pharmaceuticals
- 28 Mar 2018 This trial has been Completed in Germany according to European Clinical Trials Database record.
- 20 Jan 2018 Trial design presented at the 2018 Gastrointestinal Cancers Symposium.
- 06 Jun 2017 The ClarIDHy study is currently activated at participating sites in the US and will be activated in centers throughout Europe and in South Korea.